Share

Medtronic plc (MDT.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 3 May 2026Deep analysis 3 May 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

11 AI Advisor Reports

Select an advisor report.

Warren Buffett AI

The Value Seeker FrameworkAI Thinker

Model rating

Strong Buy

5-Year Return Est.

+89.1%

Includes 2.17% annual net dividend contribution

1. Investment Thesis — Base Case

The most reasonable path forward is a textbook reversion to intrinsic value for a wide-moat compounder. The Base Case anticipates that Medtronic will absorb the immediate, painful blows of packaging inflation, helium shortages, and TrumpRx pricing rhetoric over the next 12 months. However, the sheer inelasticity of cardiovascular and neurological demand will protect the ultimate owner's earnings. Mr. Market will eventually realize that he cannot price a life-saving monopoly like a discretionary consumer stock.

The deep moat of surgeon switching costs will prevent any meaningful market share loss.
Consumable revenue will remain rock-solid, completely ignoring the global energy recession.
Capital equipment (Hugo) will experience a brief winter, followed by a massive catch-up cycle as hospitals prioritize efficiency.
The dividend will not only be maintained but compounded, paying the patient owner to wait.
Management will deploy the fortress balance sheet to acquire distressed, innovative bolt-on technologies at bargain multiples.
As the Warsh-era liquidity shock normalizes, the multiple will expand from distressed levels back toward historical averages.

This implies a market capitalization completely justified by the immense, recurring free cash flow generated by a globally dominant, essential healthcare franchise, easily out-competing alternative capital deployments.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-04-28	131
Observed price	2021-05-11	125
Observed price	2021-05-24	127
Observed price	2021-06-02	124
Observed price	2021-06-19	124
Observed price	2021-07-11	128
Observed price	2021-07-15	125
Observed price	2021-08-02	131
Observed price	2021-08-10	126
Observed price	2021-09-01	134
Observed price	2021-09-05	134
Observed price	2021-09-27	128
Observed price	2021-10-06	126
Observed price	2021-10-19	121
Observed price	2021-11-05	122
Observed price	2021-11-18	117
Observed price	2021-11-22	115
Observed price	2021-12-01	107
Observed price	2021-12-18	102
Observed price	2022-01-09	107
Observed price	2022-01-13	109
Observed price	2022-02-04	103
Observed price	2022-02-12	103
Observed price	2022-03-02	106
Observed price	2022-03-10	105
Observed price	2022-03-28	110
Observed price	2022-04-10	112
Observed price	2022-04-23	108
Observed price	2022-04-27	106
Observed price	2022-05-10	101
Observed price	2022-05-23	103
Observed price	2022-06-14	88.5
Observed price	2022-06-18	88.3
Observed price	2022-07-01	91.2
Observed price	2022-07-14	89.0
Observed price	2022-08-05	93.3
Observed price	2022-08-18	95.1
Observed price	2022-08-31	87.9
Observed price	2022-09-13	90.5
Observed price	2022-09-26	81.4
Observed price	2022-09-30	81.2
Observed price	2022-10-04	84.9
Observed price	2022-10-30	87.3
Observed price	2022-11-08	80.7
Observed price	2022-11-21	81.9
Observed price	2022-12-08	78.1
Observed price	2022-12-17	76.8
Observed price	2023-01-03	79.5
Observed price	2023-01-16	79.9
Observed price	2023-02-03	85.6
Observed price	2023-02-07	84.5
Observed price	2023-03-01	83.0
Observed price	2023-03-05	81.0
Observed price	2023-03-09	78.3
Observed price	2023-03-31	79.4
Observed price	2023-04-22	86.0
Observed price	2023-04-30	90.8
Observed price	2023-05-13	89.0
Observed price	2023-05-22	88.1
Observed price	2023-05-30	82.9
Observed price	2023-06-17	88.3
Observed price	2023-07-08	86.5
Observed price	2023-07-26	90.2
Observed price	2023-08-03	84.1
Observed price	2023-08-12	82.8
Observed price	2023-08-25	81.4
Observed price	2023-09-16	81.7
Observed price	2023-09-24	80.0
Observed price	2023-09-29	78.2
Observed price	2023-10-16	71.9
Observed price	2023-10-29	70.2
Observed price	2023-11-15	74.0
Observed price	2023-11-20	77.1
Observed price	2023-12-11	80.8
Observed price	2023-12-20	82.0
Observed price	2024-01-06	85.8
Observed price	2024-01-24	86.0
Observed price	2024-02-01	87.6
Observed price	2024-02-06	87.2
Observed price	2024-02-27	83.5
Observed price	2024-03-11	85.1
Observed price	2024-03-24	83.6
Observed price	2024-04-02	85.5
Observed price	2024-04-15	79.4
Observed price	2024-04-24	79.6
Observed price	2024-05-15	85.5
Observed price	2024-05-20	85.3
Observed price	2024-05-28	80.9
Observed price	2024-06-19	81.0
Observed price	2024-07-02	77.3
Observed price	2024-07-11	77.1
Observed price	2024-07-19	80.6
Observed price	2024-08-06	81.0
Observed price	2024-08-27	88.7
Observed price	2024-09-05	90.9
Observed price	2024-09-18	89.0
Observed price	2024-10-05	88.0
Observed price	2024-10-18	90.6
Observed price	2024-10-23	91.0
Observed price	2024-11-13	86.2
Observed price	2024-11-26	86.3
Observed price	2024-12-09	83.2
Observed price	2024-12-13	82.0
Observed price	2024-12-31	80.1
Observed price	2025-01-08	83.1
Observed price	2025-01-26	91.1
Observed price	2025-02-12	92.0
Observed price	2025-02-21	88.5
Observed price	2025-03-06	94.1
Observed price	2025-03-23	89.3
Observed price	2025-04-01	88.7
Observed price	2025-04-18	82.0
Observed price	2025-04-22	83.4
Observed price	2025-05-14	86.1
Observed price	2025-05-23	80.7
Observed price	2025-06-09	87.9
Observed price	2025-06-26	86.0
Observed price	2025-07-05	88.6
Observed price	2025-07-09	89.1
Observed price	2025-07-27	92.4
Observed price	2025-08-04	90.1
Observed price	2025-08-17	93.1
Observed price	2025-08-30	92.1
Observed price	2025-09-21	95.4
Observed price	2025-09-25	94.2
Observed price	2025-10-04	96.9
Observed price	2025-11-03	90.5
Observed price	2025-11-12	95.5
Observed price	2025-11-16	99.7
Observed price	2025-11-25	105
Observed price	2025-12-12	99.5
Observed price	2025-12-30	96.1
Observed price	2026-01-12	97.0
Observed price	2026-01-29	101
Observed price	2026-02-02	103
Observed price	2026-02-24	96.7
Observed price	2026-02-28	97.7
Observed price	2026-03-13	87.2
Observed price	2026-04-13	88.1
Observed price	2026-04-17	86.0
Observed price	2026-04-21	83.4
Observed price	2026-05-09	76.2
Observed price	2026-05-30	74.5
Observed price	2026-06-08	82.0
Observed price	2026-06-17	78.1
Observed price	2026-07-04	83.1
Observed price	2026-07-21	82.0
Observed price	2026-07-30	85.6
Observed price	2026-08-03	86.4
Observed price	2026-08-20	93.3
Observed price	2026-08-29	90.9
Observed price	2026-09-14	93.8
Observed price	2026-09-17	92.8
Observed price	2026-09-18	92.1
Published advisor forecast	2026-05-01	80.0
Published advisor forecast	2026-08-01	81.6
Published advisor forecast	2026-11-01	84.9
Published advisor forecast	2027-02-01	90.0
Published advisor forecast	2027-05-01	93.6
Published advisor forecast	2027-08-01	96.4
Published advisor forecast	2027-11-01	98.3
Published advisor forecast	2028-02-01	102
Published advisor forecast	2028-05-01	105
Published advisor forecast	2028-08-01	107
Published advisor forecast	2028-11-01	105
Published advisor forecast	2029-02-01	109
Published advisor forecast	2029-05-01	113
Published advisor forecast	2029-08-01	115
Published advisor forecast	2029-11-01	118
Published advisor forecast	2030-02-01	122
Published advisor forecast	2030-05-01	121
Published advisor forecast	2030-08-01	126
Published advisor forecast	2030-11-01	129
Published advisor forecast	2031-02-01	133
Published advisor forecast	2031-05-01	136

2. Scenarios & Signals

Bull case

In the Bull Case, the geopolitical blockades resolve faster than anticipated, instantly alleviating the energy and plastics cost pressures. Medtronic's Hugo robotics system achieves runaway success, decisively fracturing incumbent monopolies and capturing the lion's share of deferred hospital capex.

Supply chain margins revert to historical highs within 18 months.
interventions are watered down to symbolic gestures, preserving domestic pricing power.
AI-driven diagnostics pull forward procedure volumes globally.
Share repurchases at today's distressed prices massively accrete to per-share .

This is not a dream; it is the mathematical result of a wide-moat business hitting all cylinders simultaneously.

Bear case

The Bear Case materializes if the global stagflationary environment entrenches into a multi-year depression, triggering a wave of hospital bankruptcies. Concurrently, the federal government weaponizes price controls, permanently capping margins on cardiovascular implants.

mandates 20-30% price cuts on core product lines.
costs remain permanently elevated due to a bifurcated global trade architecture.
Cash flows contract, forcing management to halt dividend growth and freeze R&D.
The stock languishes as a value trap, trading purely as a heavily regulated, low-growth utility.

We demand a margin of safety exactly because this grim reality is a statistical possibility.

Current crowd narrative

Mr. Market is currently behaving like a manic-depressive, aggressively selling Medtronic down to 80 USD. The noisy crowd is obsessively fixated on the '' pricing interventions, temporary hospital freezes due to the energy shock, and the acute supply chain bottlenecks in medical packaging and helium. The dominant narrative treats Medtronic as a generic, margin-sensitive industrial cyclical that will be crushed by . The anchoring bias is entirely focused on next quarter's margin compression rather than the multi-decade durability of the surgical ecosystem.

Alpha-gap assessment

The variant perception is relentlessly simple: Mr. Market has conflated a temporary macro-logistical nightmare with a permanent impairment of the business's moat. The crowd is fundamentally ignoring the inelastic nature of human mortality. You cannot defer a failing heart valve or a pacemaker replacement because shipping insurance premiums are high. Medtronic possesses a wide, nearly unassailable moat built on decades of surgeon training and ecosystem lock-in. While short-term cash flows face friction, the true of these non-discretionary owner earnings is radically disconnected from today's distressed quoted price. We are being offered a wonderful business at a fire-sale valuation.

Convergence catalyst

The convergence will occur when Medtronic reports consecutive quarters of resilient consumable volumes and robust , explicitly demonstrating to the market that their core life-saving interventions are immune to macroeconomic . This realization, likely to crystallize within the next 12 to 18 months as supply-chain noise settles, will force a violent upward repricing.

Macro-regime alignment

The current stagflationary environment of high rates and energy-driven inflation acts as a severe headwind for hospital capital budgets. However, Medtronic’s financial fortress—vast cash reserves, low leverage, and non-discretionary recurring revenue—makes it an absolute survivor. While weak competitors face liquidity crises, Medtronic can quietly compound value, making the thesis highly resilient to this punishing macro regime.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.8
Expected volatility regime: moderate
Convergence-cycle position: early_discovery

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Inelastic NON Discretionary Demand	Medtronic operates squarely within our circle of competence; they engineer devices that literally keep human beings alive. Heart valves, pacemakers, and neuro-stimulators are profoundly non-discretionary. Mr. Market is currently obsessed with the global energy shock and temporary hospital margin compression, but a patient experiencing heart failure does not defer surgery because the Strait of Hormuz is closed. This inelasticity provides a bedrock for owner earnings that virtually no consumer-facing business can replicate. I strongly believe this fundamental resilience will assert itself as the current geopolitical panic subsides. By providing life-saving interventions, Medtronic ensures its free cash flow generation remains incredibly durable across the darkest macroeconomic valleys, translating into long-term compounding power.	Not available%	+18.0%
Surgeon Ecosystem Switching Costs	The most beautiful economic moat a medical device company can possess is the switching cost inherent in surgical training. Surgeons spend years mastering Medtronic’s specific cardiovascular and neurological instruments. To switch to a competitor's system requires massive retraining, downtime, and elevated clinical risk. This establishes a deeply entrenched ecosystem lock-in that practically guarantees recurring revenue and pricing power. Even amid the chaos of global stagflation and supply-chain blockades, hospitals are extremely loath to overhaul their primary procedural toolkits. I emphatically view this as a widening moat; as Medtronic integrates more software and data analytics into its hardware, the friction of leaving their ecosystem transitions from difficult to nearly impossible.	Not available%	+15.0%
Relentless Dividend Compounding	When you buy a business, you are buying its future cash flows. Medtronic is a canonical Dividend Aristocrat, having compounded its payout for decades. Management operates with the rational capital allocation we demand of a partner: funding internal R&D at high returns on invested capital and distributing the excess cash directly to owners. During periods of severe market fear, such as the current energy-shock-induced panic, this robust, growing dividend acts as a gravity well for intrinsic value, enforcing a hard floor under the equity price. I am deeply convicted that reinvesting this dividend at today’s distressed 80 USD valuation will supercharge long-term returns for the patient owner.	Not available%	+12.0%
HUGO Robotic Surgery Adoption	Medtronic’s Hugo robotic-assisted surgery (RAS) system represents a spectacular reinvestment runway. While Mr. Market focuses on quarterly noise, we must look at the long-tail owner economics. Hugo is successfully challenging incumbent monopolies in the surgical robotics space by offering modularity and lower per-procedure costs. As global hospital systems eventually digest the current energy-driven margin squeeze, the imperative to drive surgical efficiency will reignite capex cycles. Medtronic is structurally positioned to capture this secular tailwind. This is not a speculative tech pipe-dream; it is the logical, high-return extension of an existing, deeply moated surgical business, expanding their addressable market and extending the durability of their competitive advantage.	Not available%	+10.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Trumprx Pricing Intervention	The rollout of the TrumpRx federal discount program and aggressive White House pharmaceutical interventions introduce real regulatory friction. When the government uses its monopsony power to strong-arm pricing, margins inevitably compress. We must intellectually honestly acknowledge that Medtronic’s cardiovascular and diabetes portfolios face pricing caps and mandatory rebates. Mr. Market is deeply fearful of this, projecting a permanent impairment to gross margins. While the business’s wide moat offers some pricing power, government decree is a formidable adversary. This regulatory pressure will act as a persistent drag on domestic revenue yields over the forecast horizon, directly taxing the true owner's earnings and forcing management to lean heavier on operational efficiency.	Not available%	-10.0%
Hospital Capex Freezes	The catastrophic energy shock driven by the Strait of Hormuz closure has severely squeezed hospital operating margins globally. When operating costs for power and basic supplies skyrocket, hospital administrators instinctively freeze capital expenditure. This creates a painful near-term friction for Medtronic’s large-ticket capital equipment, notably the Hugo robotic systems and advanced imaging hardware. While the procedural consumables remain inelastic, the heavy machinery sales will undoubtedly face delays. I am deeply concerned that this capex winter will persist as long as global energy markets remain constrained by blockade economics, temporarily depressing the high-margin equipment revenues that normally bolster Medtronic's return on invested capital.	Not available%	-8.0%
Medical Plastics Supply Shock	The Middle East conflict and the resulting blockade have triggered an acute shortage in polyethylene and other critical petrochemicals. Medtronic relies heavily on these specialized plastics for sterile medical packaging, catheters, and disposable surgical tools. This raw material squeeze introduces a severe, albeit temporary, inflation in cost of goods sold. Management will struggle to pass these input costs fully onto hospitals already buckling under stagflationary pressure. This is a classic supply-chain friction that directly erodes the owner’s cash flow. While the fortress balance sheet can absorb the blow, we must account for a meaningful suppression of operating margins until the global petrochemical logistics network normalizes.	Not available%	-6.0%
Warsh ERA Strong Dollar	The transition to the Warsh-led Federal Reserve and the resulting 'bear-steepener' shock have propelled the US dollar to extraordinary heights. For a global enterprise like Medtronic, which generates a massive portion of its revenues overseas, this creates a punishing foreign exchange translation headwind. As euros, yen, and emerging market currencies collapse against the dollar, Medtronic’s reported international earnings will be artificially compressed. I strongly believe this is a purely nominal friction rather than a degradation of intrinsic business value, but it undeniably reduces the repatriated free cash flow available for share repurchases and dividend coverage over the medium term.	Not available%	-5.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Total Victory IN Robotic Surgery Ecosystem	Should competitors stumble under supply chain constraints, Medtronic's Hugo system could rapidly seize majority market share in soft-tissue robotic surgery. If key clinical outcome data conclusively proves superior owner economics for hospitals using Hugo versus incumbent systems, adoption will inflect parabolically. This event would fundamentally alter Medtronic's growth trajectory, shifting it from a mature, slow-growth compounder into a high-growth technology platform, commanding a significantly higher earnings multiple. It would cement an insurmountable, generation-defining moat in the surgical suite.	20.0%	+25.0%
Rapid Reversal OF Global Energy Shock	If a durable diplomatic resolution in the Middle East reopens the Strait of Hormuz and normalizes global energy transit, the stagflationary pressure on global hospital systems will evaporate. This would trigger an immediate, massive unfreezing of deferred hospital capital expenditures. Medtronic would experience a violent upward re-rating as delayed orders for Hugo robotic systems and advanced surgical suites flood the order book. I strongly believe Mr. Market has priced in a permanent capex winter; a swift thaw would instantly expand operating margins and return the business to double-digit free cash flow growth.	35.0%	+15.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Systemic Hospital Solvency Crisis	Should the current stagflationary environment persist or worsen, driven by prolonged energy blockades and surging input costs, we could witness a wave of systemic insolvencies across regional hospital networks. In this dire scenario, even non-discretionary procedures would face immense funding bottlenecks. Unpaid receivables would mount, and Medtronic would be forced into massive inventory write-downs and debt restructuring. While the balance sheet is a fortress, a collapse of the core customer base would cause a brutal, multi-year contraction in cash flows and capital returns.	15.0%	-25.0%
Draconian Implementation OF Trumprx CAPS	The greatest threat to Medtronic's intrinsic value is the aggressive, unmitigated expansion of the TrumpRx program into strict, statutory price caps for cardiovascular and neurological devices. If the administration utilizes emergency wartime powers to mandate severe price reductions across Medtronic's highest-margin portfolios, the owner earnings would be structurally, permanently impaired. The business would be forced to slash vital R&D, eroding its long-term competitive moat. This scenario transforms a wonderful, high-return business into a heavily regulated, utility-like entity, severely crushing the equity's multiple.	25.0%	-20.0%

Step-by-step forecast path

Warren Buffett forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_de87bc24-07d3-5b6c-958a-6f52e85dbfd1__sb4__20260503171624
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	August 1, 2026	+2.0%	81.60	- Supply chain blockades and plastics inflation continue to bite hard on operating margins. - Mr. Market remains fearful of TrumpRx rhetoric. - However, non-discretionary consumable sales provide a hard floor, preventing further multiple collapse. - The dividend acts as a stabilizer against broad market panic.
2	November 1, 2026	+4.0%	84.86	- Q3 earnings demonstrate the profound inelasticity of heart and spine procedures. - The market begins to recognize the variant perception: healthcare demand is ignoring the energy shock. - Value investors begin accumulating shares, realizing the margin of safety is immense.
3	February 1, 2027	+6.0%	89.96	- A massive upward re-rating as global panic subsides. - The FDA backlog begins to clear, accelerating new product approvals. - Hospitals realize they must invest in efficiency, leading to a thaw in capital equipment orders.
4	May 1, 2027	+4.0%	93.55	- Management announces a robust dividend hike, signaling extreme confidence in owner economics. - TrumpRx fears diminish as implementation proves less draconian than feared. - Free cash flow margins return to historical averages.
5	August 1, 2027	+3.0%	96.36	- Steady, boring compounding takes over. - The Hugo robotic system gains tangible market share, validating the R&D investment. - The fortress balance sheet is utilized to retire shares repurchased at 2026's distressed prices.
6	November 1, 2027	+2.0%	98.29	- Normalization of the macroeconomic regime. - Foreign exchange headwinds from the Warsh-era strong dollar begin to lap, providing a clearer picture of international growth. - Predictable, wide-moat cash generation continues.
7	February 1, 2028	+4.0%	102.22	- Aging demographics push procedure volumes structural higher. - Competitors falter due to weaker balance sheets, allowing Medtronic to capture marginal market share. - The market fully digests the irrelevance of short-term macro noise on this business model.
8	May 1, 2028	+3.0%	105.29	- Strong execution in the diabetes segment as continuous glucose monitors deeply integrate with automated insulin delivery. - The moat widens as switching costs increase due to data integration. - Capital allocation remains exemplary.
9	August 1, 2028	+2.0%	107.39	- Routine compounding period. - Incremental innovation in cardiovascular pipelines keeps generic commoditization at bay. - Cash cow economics dominate the narrative.
10	November 1, 2028	-2.0%	105.24	- Mr. Market exhibits brief emotional exhaustion; broad market profit-taking affects the sector. - A minor delay in a next-generation pipeline approval causes a temporary pullback. - A classic opportunity to reinvest dividends.
11	February 1, 2029	+4.0%	109.45	- Rebound driven by superb cash flow reporting. - Global supply chains have fully realigned, and domestic manufacturing investments yield maximum efficiency. - The margin of safety is narrower, but the business quality is pristine.
12	May 1, 2029	+3.0%	112.74	- Hugo robotics achieves critical mass in global surgical suites. - The recurring revenue from robotic consumables drives a structural upward shift in gross margins. - Institutional ownership solidifies.
13	August 1, 2029	+2.0%	114.99	- Steady progression. - The business operates exactly as a patient owner expects: boringly profitable. - Excess cash continues to be returned to shareholders via buybacks and dividends.
14	November 1, 2029	+3.0%	118.44	- Expansion into emerging markets accelerates as global infrastructure recovers from the mid-2020s shocks. - Brand moat ensures Medtronic is the vendor of choice in developing healthcare systems. - Value creation is highly visible.
15	February 1, 2030	+3.0%	122.00	- Breakthroughs in neuro-stimulation open new addressable markets. - Pricing power remains intact as the life-saving nature of the products negates hospital pushback. - Return on invested capital remains well above the cost of capital.
16	May 1, 2030	-1.0%	120.78	- Valuation approaches the upper bound of intrinsic value. - A slight plateau as the market digests the multi-year run. - No fundamental deterioration, merely a pause in Mr. Market's enthusiasm.
17	August 1, 2030	+4.0%	125.61	- Resumption of upward trajectory fueled by the unstoppable demographic wave of aging global populations. - Medtronic's dominance in structural heart therapies pays massive dividends. - The economic moat proves impenetrable.
18	November 1, 2030	+3.0%	129.37	- Successful integration of bolt-on AI diagnostic acquisitions. - The transition from a pure hardware provider to a holistic data-and-device ecosystem is complete. - Owner earnings are at record highs.
19	February 1, 2031	+3.0%	133.26	- The original 2026 investment thesis is fully vindicated. - The temporary panics of blockades and price controls are forgotten history. - The power of compounding a wonderful business over time is fully evident in the stock price.
20	May 1, 2031	+2.0%	135.92	- Medtronic cements its status as a foundational pillar of any rational, long-term portfolio. - The business continues to throw off massive free cash flow with minimal maintenance capex. - A triumph of value ownership and immense patience.

Advisor and configuration

Advisor: warren_buffett__the_value_seeker__google_gemini_3_pro__20251119_preview_release
Persona: Warren Buffett
Archetype: The Value Seeker
Model: (November 19, 2025) Preview Release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: warren_buffett__the_value_seeker__google_gemini_3_pro__20251119_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: warren_buffett__the_value_seeker__google_gemini_3_pro__20251119_preview_release THINKER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats__var2
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Warren Buffett advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Elon Musk — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.